Gastrointestinal

Pancreatic adenocarcinoma: presentation, workup, and management

Clinical Overview and When to Suspect Pancreatic Adenocarcinoma

— Head/uncinate (60–70%) → painless obstructive jaundice, weight loss

— Body/tail (20–25%) → vague back pain, late presentation, often metastatic

— Diffuse (~10%)

— Older adult with painless jaundice + weight loss + light stools/dark urine

— New-onset diabetes after age 50 with weight loss (paraneoplastic in 1% within 3 years)

— Unexplained epigastric pain radiating to back, worse supine, better leaning forward

— Migratory thrombophlebitis (Trousseau sign) or unprovoked VTE in older adult

— Steatorrhea + weight loss + glucose intolerance triad

— Smoking (2x risk, #1 modifiable)

— Chronic pancreatitis (especially hereditary, PRSS1)

— Obesity, T2DM ≥5 yrs, heavy alcohol

— Family history in ≥2 first-degree relatives

— Germline mutations: BRCA1/2, PALB2, ATM, CDKN2A, STK11 (Peutz-Jeghers), Lynch syndrome, hereditary pancreatitis

— African American race, male sex

— No general population screening (USPSTF Grade D)

— High-risk individuals (germline mutation carriers, ≥2 affected FDRs): annual MRI/MRCP or EUS starting at age 50 (or 10 yrs before earliest family case), through CAPS consortium guidance

Board pearl: New-onset diabetes plus unintentional weight loss in a patient >50 is a classic PDAC stem — order abdominal imaging (CT pancreas protocol), not just an A1c recheck. The pancreas is being destroyed by tumor, not failing from insulin resistance.

Step 3 management: Suspicion threshold should be low in any older patient with painless jaundice — go directly to multiphase contrast-enhanced CT, not RUQ ultrasound alone (US misses body/tail lesions).

Pancreatic ductal adenocarcinoma (PDAC) is the 3rd leading cause of US cancer death; 5-year survival ~12% overall, <3% for metastatic disease.

Median age at diagnosis is ~70; rare before 45 unless hereditary syndrome.

Anatomic distribution:

When to suspect on Step 3:

Risk factors (high yield):

Screening:

Presentation Patterns and Key History

— Painless jaundice (compression of intrapancreatic CBD)

— Weight loss (often >10% body weight)

— Anorexia/early satiety

— Epigastric, dull, gnawing, radiating to mid-back

— Worse supine and after meals; relieved leaning forward (prayer position)

— Severe back pain suggests retroperitoneal/celiac plexus invasion → often unresectable

— Vague abdominal/back pain

— Weight loss alone

— Often present with liver, peritoneal, or pulmonary mets

— Left supraclavicular Virchow node or periumbilical Sister Mary Joseph nodule

— Trousseau syndrome: migratory superficial thrombophlebitis; recurrent unprovoked VTE

— New-onset diabetes within prior 24 months (esp. lean, older patient)

— Depression preceding diagnosis (classic association, mechanism unclear)

— Steatorrhea, foul greasy stools → exocrine insufficiency

— Pruritus from cholestasis (bile salt deposition)

— Smoking pack-years, alcohol

— Family history of pancreatic, breast, ovarian, colon, melanoma cancers

— Prior pancreatitis episodes

— Medication review (rule out drug-induced jaundice)

— Travel/hepatitis exposure (rule out viral)

Key distinction: Painful jaundice with fever/chills + RUQ tenderness = ascending cholangitis/choledocholithiasis. Painless jaundice + Courvoisier sign + weight loss = malignancy until proven otherwise.

Board pearl: Recurrent unprovoked DVT in an older patient with vague abdominal symptoms — image the pancreas. Trousseau predates the cancer diagnosis in up to 20% of cases.

Classic triad for pancreatic head cancer:

Pain characteristics:

Body/tail cancer presentations (no biliary obstruction → late):

Paraneoplastic and systemic clues (high-yield):

History elements to elicit:

Courvoisier sign: palpable, non-tender gallbladder + jaundice → malignant biliary obstruction (PDAC, cholangiocarcinoma, ampullary), not choledocholithiasis (stones produce a scarred, non-distensible GB).

Physical Exam Findings

— Cachectic, temporal wasting, sarcopenia

— Scleral icterus when bilirubin >2.5–3 mg/dL

— Jaundice of skin and mucous membranes

— Excoriations from pruritus

— Courvoisier sign: palpable, non-tender, distended gallbladder (RUQ)

— Epigastric fullness or palpable mass (advanced disease)

— Hepatomegaly suggesting liver metastases; nodular liver edge

— Ascites → peritoneal carcinomatosis (poor prognosis)

— Succussion splash if duodenal obstruction (gastric outlet)

— Virchow node: left supraclavicular lymphadenopathy

— Sister Mary Joseph nodule: firm periumbilical metastasis

— Blumer shelf: rectal-shelf metastasis on DRE (pouch of Douglas)

— Trousseau migratory thrombophlebitis: tender erythematous cords in varying limb locations

— Acanthosis nigricans (paraneoplastic, less common)

— Usually hemodynamically stable at presentation

— Concerning findings: tachycardia + hypotension → consider GI bleed (duodenal invasion), septic cholangitis (if obstructed + infected), or PE from hypercoagulability

— Volume status: orthostatics if poor PO intake/dehydration

— Calculate performance status (ECOG) — drives treatment eligibility

— Splenomegaly + gastric varices → left-sided portal hypertension from splenic vein thrombosis (body/tail tumors compress splenic vein)

— Migratory phlebitis on legs/arms

— Muscle wasting (temporalis, interosseous)

CCS pearl: On a CCS case with painless jaundice, your initial physical should explicitly include abdominal palpation, lymph node survey (left supraclavicular), and DRE — these maneuvers can detect metastases that change staging and avoid futile workup.

Board pearl: ECOG performance status (0–4) determines whether a patient is a candidate for FOLFIRINOX vs gemcitabine-based regimens vs best supportive care — document it explicitly in every PDAC patient.

General appearance:

Abdominal exam:

Lymphatic and skin signs (advanced/metastatic):

Hemodynamic and systemic assessment:

Stigmata to actively look for:

Diagnostic Workup — Initial Labs and Imaging

— CBC: anemia (chronic disease, occult GI bleed)

— CMP:

— ↑ Total/direct bilirubin, ↑ alk phos, ↑ GGT → cholestatic pattern

— AST/ALT mildly elevated; if >5x normal think hepatocellular instead

— Glucose elevation (new diabetes)

— Hypoalbuminemia, malnutrition markers

— Coags (PT/INR): prolonged in obstructive jaundice (vit K malabsorption) — correctable with parenteral vitamin K

— Lipase/amylase: may be normal or mildly elevated; not diagnostic

— Hepatitis serologies to exclude viral cause of jaundice

— CA 19-9: most useful marker

— Sensitivity ~80%, specificity ~80% at cutoff 37 U/mL

— False positives: biliary obstruction (cholangitis, choledocholithiasis) — recheck after biliary decompression

— False negatives: ~5–10% of population are Lewis antigen negative and cannot produce CA 19-9

— Use for monitoring response and recurrence, not screening

— CEA: nonspecific, occasionally adjunct

— Multiphase contrast-enhanced CT (arterial + portal venous + delayed phases) with thin pancreatic cuts

— Assesses: primary mass, vascular involvement (SMA, SMV, celiac, portal vein), nodal disease, liver mets

— Determines resectability: resectable, borderline resectable, locally advanced, metastatic

— Hypoattenuating mass with double-duct sign (dilated CBD + pancreatic duct) is classic

— MRI/MRCP: better soft tissue characterization, liver lesion evaluation, ductal anatomy

Board pearl: A normal CA 19-9 does not rule out pancreatic cancer (Lewis-negative ~5–10%). And an elevated CA 19-9 in cholangitis is unreliable — decompress the biliary tree first, then recheck.

Step 3 management: For suspected PDAC, multiphase pancreas-protocol CT is the first-line imaging study, not RUQ ultrasound. US is reasonable only as a quick initial sort for the jaundiced patient before progressing to CT.

Initial labs:

Tumor markers:

First-line imaging — Pancreas-protocol CT:

If CT non-diagnostic or biliary detail needed:

Diagnostic Workup — Advanced and Confirmatory Studies

— Highest sensitivity for small pancreatic lesions (<2 cm)

— Preferred modality for tissue diagnosis prior to neoadjuvant therapy or non-operative management

— Allows nodal sampling and vascular invasion assessment

— Lower seeding risk than percutaneous biopsy (especially important for resectable disease)

— Therapeutic, not primarily diagnostic in PDAC

— Used to place biliary stents for symptomatic jaundice, cholangitis, or before neoadjuvant therapy

— Metal stents preferred over plastic for longer patency (≥3 months expected survival)

— Can obtain brushings for cytology (low yield, ~50%)

— CT chest to assess pulmonary mets

— Pelvic imaging (MRI/CT) if indicated

— PET-CT: not routine; selective use for indeterminate findings

— Staging diagnostic laparoscopy: consider for body/tail tumors, high CA 19-9 (>500), borderline resectable to detect occult peritoneal disease before laparotomy

— Upfront resectable disease: tissue confirmation not mandatory before surgery if imaging is classic — surgeon may proceed

— Neoadjuvant chemo planned, borderline/locally advanced, or metastatic: tissue required before therapy → EUS-FNB preferred

— Percutaneous biopsy only for metastatic site (liver) when needed

— Germline testing for ALL patients with PDAC regardless of family history (NCCN)

— Tumor molecular profiling for BRCA1/2, PALB2, KRAS, MSI/MMR, NTRK, HER2 to guide targeted therapy

Key distinction: ERCP = therapeutic (stent), EUS = diagnostic (biopsy). On Step 3, if the question asks the best test for tissue diagnosis → EUS-FNB. If asking how to relieve jaundice → ERCP with stent.

Board pearl: Universal germline testing in all PDAC patients is now standard — BRCA/PALB2 mutations open access to PARP inhibitors (olaparib) in maintenance therapy and have implications for relatives.

Endoscopic ultrasound (EUS) with FNA/FNB:

ERCP:

Staging completion:

Tissue diagnosis timing:

Genetic and molecular testing (now standard):

Risk Stratification and First-Line Management Logic

— Resectable: no vascular contact with SMA/celiac/CHA; ≤180° SMV/PV contact without contour irregularity

— Borderline resectable: limited vascular contact reconstructable

— Locally advanced/unresectable: >180° SMA/celiac involvement, unreconstructable SMV/PV occlusion

— Metastatic: liver, peritoneal, distant nodes, lung

— Resectable: neoadjuvant chemotherapy (increasingly preferred, esp. mFOLFIRINOX) → surgery → adjuvant chemo; OR upfront surgery → adjuvant chemo (mFOLFIRINOX preferred if fit, ECOG 0–1)

— Borderline resectable: neoadjuvant chemo ± radiation → restaging → surgery if downstaged

— Locally advanced: induction chemo → consider chemoradiation; rare conversion to resection

— Metastatic: systemic chemo + palliation; no role for resection

— ECOG 0–1, good organ function: mFOLFIRINOX (most aggressive, best survival)

— ECOG 1–2 or borderline fitness: gemcitabine + nab-paclitaxel

— ECOG 2 or frail: gemcitabine monotherapy or best supportive care

— ECOG 3–4: best supportive care/hospice

— Biliary decompression if jaundiced and chemo planned (bilirubin <2–3 usually required)

— Nutritional support: dietitian, pancreatic enzyme replacement (PERT)

— Glycemic control

— VTE prophylaxis consideration (high baseline thrombotic risk)

— Smoking cessation, alcohol cessation

— Vaccinations, dental clearance if appropriate

CCS pearl: In a borderline-resectable case, your CCS orders should include: CA 19-9 baseline, pancreas CT, EUS-FNB for tissue, biliary stenting if jaundiced, port placement, oncology referral, nutrition consult, and germline testing referral — all before chemo day 1.

Board pearl: Only 15–20% of PDAC patients are resectable at diagnosis; surgery alone (without chemo) is rarely the answer on Step 3.

Resectability staging (NCCN) drives all management:

Treatment pathway by stage:

Performance status and comorbidity determine regimen:

Pre-treatment optimization (CCS priorities):

Pharmacotherapy — First-Line Chemotherapy Regimens

— First-line for fit patients (ECOG 0–1) in adjuvant, neoadjuvant, and metastatic settings

— PRODIGE/PRODIGE-24: adjuvant FOLFIRINOX → median OS 54 mo vs 35 mo gemcitabine

— Toxicities: neutropenia, diarrhea, peripheral neuropathy (oxaliplatin), fatigue, mucositis

— Requires G-CSF support in many; dose modifications common

— Contraindicated: UGT1A1 *28 homozygotes (severe irinotecan toxicity) → screen if known

— Avoid with significant neuropathy, hepatic dysfunction, poor PS

— Alternative first-line, particularly metastatic

— MPACT trial: median OS 8.5 vs 6.7 mo (gem alone)

— Toxicities: myelosuppression, neuropathy, fatigue, rash

— Better tolerated than FOLFIRINOX in marginal performance status

— Frail patients, ECOG 2, significant comorbidity

— Modest benefit but low toxicity

— Olaparib (PARP inhibitor): germline BRCA1/2 mutation, no progression after 16 wks platinum-based chemo (POLO trial)

— Pembrolizumab: MSI-high/dMMR tumors (rare, ~1% of PDAC)

— Larotrectinib/entrectinib: NTRK fusion (very rare)

— KRAS G12C inhibitors: emerging

— PERT (pancrelipase) with meals/snacks for exocrine insufficiency

— Antiemetics: 5-HT3 + dexamethasone + NK1 for chemo

— G-CSF (pegfilgrastim) prophylaxis with FOLFIRINOX

— LMWH for VTE (preferred over DOACs historically; apixaban/edoxaban acceptable per recent guidelines, avoid in luminal GI tumors with bleeding risk)

— Opioids and adjuvants for pain

Board pearl: A new PDAC patient with germline BRCA2 mutation who responds to platinum chemotherapy → olaparib maintenance is the right next step.

Step 3 management: Always check bilirubin and performance status before initiating chemotherapy — uncontrolled hyperbilirubinemia → stent first; ECOG ≥3 → palliative care, not FOLFIRINOX.

mFOLFIRINOX (oxaliplatin, irinotecan, leucovorin, 5-FU bolus + infusion):

Gemcitabine + nab-paclitaxel:

Gemcitabine monotherapy:

Maintenance and targeted therapy:

Supportive medications:

Surgical and Procedural Management

— For tumors of head, uncinate, periampullary region

— Removes: pancreatic head, duodenum, distal CBD, gallbladder, proximal jejunum, ± distal stomach (classic vs pylorus-preserving)

— Reconstruction: pancreaticojejunostomy + hepaticojejunostomy + gastrojejunostomy

— High-volume center (>20 Whipples/year) significantly reduces mortality (<3%) vs low-volume (>10%)

— Complications: postoperative pancreatic fistula (POPF), delayed gastric emptying, anastomotic leak, hemorrhage, infection, new diabetes, exocrine insufficiency

— For body/tail tumors

— Splenectomy → post-splenectomy vaccinations (pneumococcal, meningococcal, Hib) ideally 2 wks pre-op or 2 wks post-op

— Rare; reserved for diffuse disease or multifocal IPMN with cancer

— Results in brittle diabetes + complete exocrine insufficiency

— SMV/PV resection acceptable for borderline resectable; arterial resection generally avoided

— Biliary obstruction: ERCP with self-expanding metal stent (SEMS); percutaneous transhepatic drainage if ERCP fails; surgical bypass (hepaticojejunostomy) only if at laparotomy

— Gastric outlet obstruction: endoscopic duodenal stent (short prognosis) or surgical gastrojejunostomy (longer prognosis)

— Celiac plexus neurolysis (EUS-guided or percutaneous): for refractory tumor pain — opioid-sparing

— Initiate within 8–12 weeks of surgery

— Standard: mFOLFIRINOX × 6 months if fit; otherwise gemcitabine ± capecitabine

CCS pearl: Post-Whipple, key orders include: NG decompression, JP drain monitoring (amylase on POD 3 — POPF screen), DVT prophylaxis, glucose monitoring, early enteral nutrition, infection surveillance, and timely adjuvant chemo referral by 6–8 weeks.

Board pearl: Refer Whipples to high-volume centers — this is a documented quality/value-based care principle and a common Step 3 systems question.

Whipple procedure (pancreaticoduodenectomy):

Distal pancreatectomy ± splenectomy:

Total pancreatectomy:

Vascular resection/reconstruction:

Palliative procedures:

Adjuvant therapy:

Special Populations — Elderly and Renal/Hepatic Impairment

— Chronologic age alone is not a contraindication to resection or chemotherapy

— Use geriatric assessment: comprehensive frailty score, Charlson comorbidity index, ECOG, IADLs

— Whipple can be performed safely in fit octogenarians at high-volume centers

— Chemotherapy: FOLFIRINOX rarely tolerated >75; favor gemcitabine + nab-paclitaxel or gemcitabine alone

— Increased risk of: delirium, falls, dehydration with diarrhea, neutropenic infections

— Polypharmacy review: discontinue inappropriate meds; check drug–drug interactions

— Capecitabine: dose-reduce if CrCl 30–50; avoid if CrCl <30

— Oxaliplatin: dose adjust for CrCl <30

— Cisplatin (rarely used in PDAC): avoid <60

— 5-FU: hepatic metabolism, generally fine in renal impairment

— Gemcitabine: limited data, use caution

— Iodinated contrast for CT: hold/hydrate per AKI risk; MRI alternative

— Decompress biliary tree first if obstructive (bilirubin >2–3)

— Once decompressed and LFTs improve, most chemo agents tolerated

— Irinotecan: dose reduce if bilirubin 1.5–3; avoid if >3 (severe toxicity, UGT1A1)

— Nab-paclitaxel: dose modify with elevated bilirubin

— Watch for decompensation in those with cirrhosis or mets — synthetic dysfunction → coagulopathy

— Consider before fluoropyrimidines (5-FU, capecitabine) — patients with DPYD variants have life-threatening toxicity

Board pearl: Before starting FOLFIRINOX in a 78-year-old, calculate CrCl, check bilirubin, screen UGT1A1 and DPYD if available, and document geriatric assessment — Step 3 loves the "appropriate pre-treatment evaluation" question.

Key distinction: Hyperbilirubinemia from obstruction is correctable with stenting and not a permanent contraindication to chemo, unlike hyperbilirubinemia from advanced hepatic mets.

Elderly patients (>75):

Renal impairment:

Hepatic impairment (often from biliary obstruction or mets):

DPYD deficiency screening:

Special Populations — Pregnancy, Pediatrics, and Hereditary Syndromes

— PDAC in pregnancy is exceedingly rare (median age 70); when it occurs, usually advanced

— Imaging: MRI without gadolinium preferred; ultrasound first; avoid CT contrast in 1st trimester if possible

— Treatment: balance maternal benefit vs fetal risk; chemo generally avoided in 1st trimester (teratogenic); gemcitabine has limited safety data in 2nd/3rd trimesters

— Multidisciplinary: MFM, oncology, surgery — and patient autonomy in shared decision-making must dominate

— PDAC essentially does not occur in children; pediatric pancreatic tumors are pancreatoblastoma, solid pseudopapillary neoplasm (Frantz tumor), or neuroendocrine — different biology and prognosis

— If pediatric pancreatic mass: refer to peds oncology, not adult PDAC pathways

— Hereditary breast-ovarian (BRCA1/2, PALB2): 5–10x risk; PARP inhibitor sensitive

— Peutz-Jeghers (STK11/LKB1): 30–40% lifetime PDAC risk; mucocutaneous pigmentation + hamartomas

— Familial atypical multiple mole melanoma (CDKN2A/p16): melanoma + PDAC; up to 17% lifetime risk

— Lynch syndrome (MMR genes): modest PDAC increase; MSI-high tumors → pembrolizumab eligible

— Hereditary pancreatitis (PRSS1): 40–55% lifetime risk; recurrent childhood pancreatitis

— Familial pancreatic cancer: ≥2 FDR affected without identified syndrome

— Annual MRI/MRCP and/or EUS starting age 50 (or 10 yrs before earliest case, age 40 in PRSS1, age 30–35 in Peutz-Jeghers)

— Referral to specialized high-risk pancreas surveillance program

— Genetic counseling for family members

Board pearl: A patient with PDAC and a confirmed BRCA2 germline mutation mandates genetic counseling for first-degree relatives — counsel patient, refer family. This is a frequent Step 3 ethics/genetics crossover.

Step 3 management: Universal germline testing in all PDAC patients per NCCN regardless of family history or age.

Pregnancy:

Pediatrics:

Hereditary syndromes (Step 3 favorite):

Surveillance for high-risk individuals:

Complications and Adverse Outcomes

— Obstructive jaundice: pruritus, coagulopathy (vit K deficiency), cholangitis if infected

— Gastric outlet obstruction (GOO): 10–20%, presents with vomiting, early satiety, weight loss → stent or gastrojejunostomy

— Tumor pain: severe neuropathic back pain from celiac plexus invasion → opioids + adjuvants + celiac plexus neurolysis

— Duodenal/biliary bleeding: GI bleed from tumor erosion

— Exocrine pancreatic insufficiency: steatorrhea, weight loss, fat-soluble vitamin deficiency → PERT with meals, ADEK supplementation

— Endocrine insufficiency: new or worsening diabetes; brittle after total pancreatectomy

— Cachexia (multifactorial, paraneoplastic via IL-6, TNF-α): nutritional counseling, sometimes appetite stimulants (mirtazapine, megestrol)

— VTE risk markedly elevated (Khorana score high); DVT, PE, mesenteric/splenic vein thrombosis

— Trousseau syndrome migratory thrombophlebitis

— Treatment-related: LMWH or apixaban/edoxaban for active cancer VTE

— Anemia from chronic disease, occult bleeding, marrow suppression

— FOLFIRINOX: febrile neutropenia, diarrhea (irinotecan), peripheral neuropathy (oxaliplatin), mucositis

— Gem/nab-pac: myelosuppression, neuropathy, pneumonitis (rare)

— Post-Whipple: pancreatic fistula, delayed gastric emptying, anastomotic stricture, marginal ulcer, late diabetes

— Massive ascites, hepatic failure, malignant biliary stricture progression, bowel obstruction

— Pain crisis

— Cachexia-related immobility, pressure ulcers

Board pearl: A patient with PDAC presenting with new leg swelling and pleuritic chest pain — get a CT-PA; PDAC has one of the highest VTE rates of any malignancy.

Step 3 management: Start PERT empirically in any PDAC patient with steatorrhea, weight loss, or post-pancreatectomy — don't wait for elastase testing.

Local/tumor-related complications:

Metabolic and nutritional:

Hematologic/thrombotic:

Treatment-related:

End-stage complications:

When to Escalate Care — ICU, Consults, and Inpatient Triage

— Ascending cholangitis (Charcot triad: fever, RUQ pain, jaundice; Reynolds pentad adds shock, AMS) → IV antibiotics + urgent ERCP within 24–48 hrs

— Severe sepsis from any source (neutropenic, biliary, intra-abdominal)

— Uncontrolled pain requiring IV opioids/PCA

— Intractable vomiting from gastric outlet obstruction → NG decompression, IVF, urgent endoscopy

— Massive GI bleed from tumor erosion → endoscopy, IR embolization

— Acute PE/DVT requiring monitoring and anticoagulation initiation

— Febrile neutropenia on chemo (ANC <500 + temp ≥38.3°C) → empiric broad-spectrum (cefepime or pip-tazo)

— Hemodynamic instability (septic shock from cholangitis, hemorrhagic shock)

— Need for vasopressors, mechanical ventilation

— Respiratory failure (massive PE, pneumonia, malignant effusion)

— Severe metabolic derangement (DKA from new diabetes, severe AKI)

— GI/advanced endoscopy — biliary stenting, EUS-FNB, GOO stenting

— Surgical oncology — resectability assessment, Whipple, distal pancreatectomy

— Medical oncology — systemic therapy decisions

— Radiation oncology — SBRT for borderline resectable/locally advanced

— Interventional radiology — percutaneous biliary drainage if ERCP fails, port placement, drain management

— Palliative care — EARLY (concurrent with oncology) — improves QOL and survival (Temel-type data)

— Nutrition, social work, genetic counseling, psychiatry (depression is common)

— Confirm goals of care before each escalation

— Document code status at admission

— Engage hospice early when systemic therapy no longer offered

CCS pearl: In an unstable PDAC patient with fever, jaundice, hypotension → fluids + broad-spectrum antibiotics + urgent ERCP/biliary decompression; do not delay biliary drainage waiting for cultures.

Step 3 management: Early palliative care consultation alongside active oncologic treatment is now standard of care in advanced PDAC — a frequently tested practice principle.

Indications for inpatient admission:

ICU triage criteria:

Consults to obtain:

Disposition decisions:

Key Differentials — Same-Category (Pancreatic and Periampullary) Causes

— Also causes painless jaundice + Courvoisier sign

— Imaging: biliary stricture, less mass-like, periductal thickening

— CA 19-9 elevated; histology distinguishes

— Slightly better prognosis than PDAC if resected

— Arises at ampulla of Vater

— Best prognosis of the periampullary cancers (5-yr survival 30–50%)

— Often presents with fluctuating jaundice ± occult GI bleed (silver stools = melena + acholic stool)

— ERCP visualizes ampullary mass; biopsy diagnostic

— Rare; may mimic PDAC if periampullary

— Better resection outcomes

— Associated with FAP, Lynch syndrome, celiac disease

— Slower growing, often functional (insulinoma, gastrinoma, VIPoma, glucagonoma)

— Non-functional pNET → mass effect

— Hypervascular on arterial phase CT (vs hypovascular PDAC)

— Different markers (chromogranin A, NSE); different treatment (everolimus, sunitinib, PRRT)

— MEN1 association

— Young women, indolent, excellent prognosis with resection

— Heterogeneous mass with hemorrhage

— Premalignant cystic lesions

— Main-duct IPMN with mural nodules/dilation >10 mm → high malignant risk → resect

— MCN in body/tail, women, ovarian-type stroma

— Can mimic PDAC clinically and on imaging — mass-forming pancreatitis

— Type 1 AIP: IgG4-related, sausage-shaped pancreas, responds to steroids

— Elevated serum IgG4

— Critical to distinguish — avoid unnecessary Whipple

Key distinction: Hypovascular pancreatic mass = PDAC; hypervascular = pNET. Different chemo, different prognosis, different management entirely. Always check arterial-phase enhancement pattern.

Board pearl: Always consider autoimmune pancreatitis in a suspected PDAC case — IgG4 level + steroid trial can spare a patient unnecessary Whipple.

Cholangiocarcinoma (distal):

Ampullary adenocarcinoma:

Duodenal adenocarcinoma:

Pancreatic neuroendocrine tumors (pNET):

Solid pseudopapillary neoplasm (Frantz tumor):

IPMN (intraductal papillary mucinous neoplasm) / MCN (mucinous cystic neoplasm):

Chronic pancreatitis / autoimmune pancreatitis (AIP):

Key Differentials — Other-Category Causes of Painless Jaundice and Pancreatic Mass

— Usually painful (RUQ colic) with jaundice; can occasionally be painless

— US shows CBD stones, dilation; gallbladder typically small/scarred (no Courvoisier)

— Management: ERCP with stone extraction

— Younger patient, associated with IBD (especially UC)

— MRCP: beaded intrahepatic and extrahepatic ducts

— Risk of cholangiocarcinoma

— Pruritus, fatigue, intermittent jaundice

— Middle-aged women, fatigue, pruritus, xanthelasmas

— Anti-mitochondrial antibody positive

— Elevated alk phos with normal imaging

— Estrogens, anabolic steroids, amoxicillin-clavulanate, erythromycin, TPN

— History critical

— Usually hepatocellular (ALT/AST >>> alk phos), but cholestatic variants exist

— Travel/exposure history; serologies

— Colorectal, breast, lung primaries can present with liver lesions; pancreas may be normal

— Need primary site workup (colonoscopy, mammography, chest CT)

— Bulky lymphadenopathy, B symptoms

— Avoid Whipple — chemotherapy/rituximab is curative, biopsy first

— Immunocompromised, endemic exposure

— Granulomatous inflammation, AFB stain, fungal cultures

— Cystic, not solid; serous = benign honeycomb microcysts

— Less commonly confused but appear on differential

Key distinction: A pancreatic mass with massive peripancreatic lymphadenopathy in a younger patient with B symptoms → biopsy first, suspect lymphoma; do not proceed to Whipple.

Board pearl: Painless jaundice in a 30-year-old with ulcerative colitis → think PSC ± cholangiocarcinoma, not PDAC. Age and IBD context flip the differential completely.

Choledocholithiasis:

Primary sclerosing cholangitis (PSC):

Primary biliary cholangitis (PBC):

Drug-induced cholestasis:

Viral hepatitis (A, B, C, E):

Liver metastases mimicking primary pancreatic mass:

Lymphoma involving pancreas/peripancreatic nodes:

Tuberculosis or fungal pancreatic abscess:

Pseudocyst, retention cyst, serous cystadenoma:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Adjuvant chemotherapy referral — start within 6–12 weeks (mFOLFIRINOX preferred; gemcitabine ± capecitabine alternative)

— PERT (pancrelipase) 25,000–50,000 units lipase with meals, half-dose with snacks; titrate to symptom control

— Insulin or oral hypoglycemics for new/worsening diabetes — endocrinology referral if brittle

— PPI for marginal ulcer prophylaxis post-Whipple (often continued long-term)

— VTE prophylaxis — extended LMWH or apixaban for 4 weeks post-major abdominal cancer surgery

— Fat-soluble vitamin replacement (A, D, E, K)

— Vaccinations: if splenectomy → pneumococcal (PCV20 or PCV15+PPSV23), meningococcal (ACWY + B), Hib; annual flu, COVID, RSV per guidelines

— Iron, B12 supplementation as indicated post-gastric resection

— Smoking cessation (varenicline/bupropion/NRT; reduces recurrence risk and overall mortality)

— Alcohol cessation counseling

— Balanced, calorie-dense diet; small frequent meals

— Physical activity/rehabilitation as tolerated

— Weight monitoring

— Depression screening at every visit (high prevalence)

— Social work for financial toxicity, transportation

— Caregiver support

— Advance care planning even in curative-intent setting

— Confirm germline testing was performed — if not, order it

— Refer first-degree relatives of BRCA/PALB2/Lynch/PJS patients for genetic counseling

— Enroll high-risk relatives in surveillance programs

— Symptom-focused: pain, nausea, anorexia, depression management

— Hospice referral when chemo no longer offered or PS declines

Step 3 management: At every post-Whipple visit, verify the patient is on PERT, glycemic monitoring, PPI, and adjuvant chemo schedule — these four are commonly the "missed" item in a question stem.

Board pearl: Extended postoperative VTE prophylaxis for 4 weeks after major cancer abdominal surgery (including Whipple) is an evidence-based standard.

Post-resection (curative-intent) discharge bundle:

Lifestyle and counseling:

Psychosocial:

Family/genetics:

Palliative-intent patients:

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— History, physical, CA 19-9 every 3–6 months × 2 years, then every 6–12 months through year 5

— CT chest/abdomen/pelvis every 3–6 months × 2 years, then every 6–12 months

— No specific recommendation beyond 5 years given low cure rate, but individualize

— Rising CA 19-9 → restage with imaging before assuming recurrence

— Consider biliary stenosis as a confounder (re-elevation in obstructed patients)

— Weight, BMI, albumin, prealbumin at each visit

— Fecal elastase if exocrine insufficiency suspected (<200 µg/g)

— Fat-soluble vitamin levels annually (A, D, 25-OH, E, INR for K)

— B12, iron, calcium, magnesium

— A1c every 3 months in pancreatogenic ("type 3c") diabetes — often insulin-requiring

— Hypoglycemia awareness counseling (brittle post-pancreatectomy)

— Endocrinology partnership

— New back pain → recurrence imaging

— New jaundice → biliary stricture (benign vs malignant) → MRCP/ERCP

— New weight loss → recurrence, PERT failure, depression

— Leg swelling → VTE surveillance

— Physical therapy for deconditioning, post-op recovery

— Occupational therapy for ADLs

— Pulmonary rehab if relevant

— Cancer survivorship clinic

— Recurrence symptoms — when to call

— Medication adherence (PERT, insulin, PPI)

— Travel with cancer (vaccinations, anticoagulation considerations)

— Sexual health, fertility (relevant in younger patients)

— Driving/return to work after Whipple (typically 6–8 weeks)

Step 3 management: Surveillance imaging + CA 19-9 every 3–6 months for 2 years, plus comprehensive nutritional and glycemic follow-up — the multidisciplinary loop is the testable concept.

Board pearl: A patient post-Whipple with weight loss and steatorrhea — escalate PERT dose first (often under-dosed); only then investigate for recurrence.

Post-curative resection surveillance (NCCN):

CA 19-9 trends:

Nutritional follow-up:

Glycemic monitoring:

Symptom-directed evaluation:

Rehabilitation:

Counseling topics:

Ethical, Legal, and Patient Safety Considerations

— PDAC carries grave prognosis; informed consent for Whipple, FOLFIRINOX, ERCP must include realistic survival statistics, treatment toxicities, alternatives including hospice

— Avoid "therapeutic privilege" — patients have a right to honest prognostic information; SPIKES protocol useful

— Shared decision-making is mandatory for treatment selection (aggressive vs comfort-focused)

— Document code status and advance directives at diagnosis, before each chemo cycle, and before surgery

— Concurrent palliative care alongside oncologic treatment is evidence-based and improves QOL and possibly survival

— Not synonymous with hospice — common misconception in patients and providers

— Discuss POLST/MOLST in advanced disease

— Advanced PDAC patients may develop hepatic encephalopathy, opioid-related delirium, brain mets (rare) → assess decisional capacity before major treatment decisions

— Identify healthcare proxy/surrogate early

— Universal germline testing has implications for relatives — obtain informed consent including discussion of incidental findings and family ramifications

— GINA protects employment/health insurance discrimination, not life/disability/long-term care insurance — disclose this

— Post-Whipple discharge is high-risk for: PERT under-dosing, missed adjuvant chemo, drain mismanagement, VTE, marginal ulcer, infections

— Structured discharge summary, medication reconciliation, early follow-up within 1–2 weeks with surgical oncology

— Closed-loop communication of pathology results, especially margin status and germline testing — never let critical results fall into the gap

— Outcomes substantially better at high-volume centers — discuss referral; failure to offer may be a quality-of-care issue

— Honor patient wishes regarding hospitalizations, ICU, CPR; do not pursue futile interventions

Step 3 management: Within 1–2 weeks of Whipple discharge, schedule a structured visit to verify adjuvant chemo plan, PERT dosing, glycemic management, wound/drain status, VTE prophylaxis, and germline testing follow-through — this transition is where Step 3 safety questions live.

Board pearl: Initiate palliative care concurrently with oncology referral in metastatic PDAC — it is standard of care, not a "giving up" step.

Goals-of-care and informed consent:

Early palliative care integration:

Capacity assessment:

Genetic testing ethics:

Transitions-of-care safety (Step 3 favorite):

High-volume center referral:

End-of-life:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: Painless jaundice in an older patient — multiphase pancreas CT first, not ultrasound alone.

Painless jaundice + weight loss + Courvoisier sign → PDAC head until proven otherwise

Trousseau syndrome (migratory thrombophlebitis) → classic PDAC paraneoplastic

New diabetes + weight loss after age 50 → image the pancreas

Double-duct sign on CT/MRCP = dilated CBD + pancreatic duct → ampullary/head mass

CA 19-9: monitor response/recurrence; Lewis-negative 5–10% cannot produce it

Hypovascular pancreatic mass = PDAC; hypervascular = pNET

KRAS mutation in ~90% of PDAC; TP53, CDKN2A, SMAD4 follow

SMAD4 loss → worse prognosis, distant metastatic pattern

mFOLFIRINOX = best survival, requires ECOG 0–1

Gem/nab-paclitaxel = alternative first-line, more tolerable

Olaparib maintenance for germline BRCA1/2 after platinum response

Pembrolizumab for MSI-high/dMMR PDAC (~1%)

Whipple mortality <3% at high-volume, >10% at low-volume centers

Pancreatic fistula = most common Whipple complication (POPF, drain amylase POD 3)

Post-Whipple delayed gastric emptying very common; supportive care

PERT with meals for exocrine insufficiency; titrate to stool quality

Pancreatic exocrine insufficiency → fat-soluble vitamin deficiency (ADEK)

Pancreatogenic diabetes = type 3c, often insulin-requiring, brittle

Hereditary syndromes: BRCA1/2, PALB2, ATM, CDKN2A, STK11 (Peutz-Jeghers), PRSS1, Lynch

Peutz-Jeghers: 30–40% lifetime PDAC risk, mucocutaneous pigmentation

Hereditary pancreatitis (PRSS1): 40–55% lifetime risk

Universal germline testing for ALL PDAC patients per NCCN

Smoking is #1 modifiable risk factor

Splenic vein thrombosis + gastric varices = left-sided portal hypertension (body/tail tumor)

Celiac plexus neurolysis for refractory tumor pain

SEMS (metal biliary stent) preferred if survival >3 months

Tissue diagnosis: EUS-FNB > percutaneous; not required if upfront resectable + classic imaging

15–20% resectable at diagnosis; 5-yr OS ~12% overall, ~30% after Whipple + adjuvant

Khorana score high in PDAC → consider primary VTE prophylaxis in chemo outpatients

Autoimmune pancreatitis (IgG4) mimics PDAC — check IgG4 before Whipple

Sister Mary Joseph, Virchow, Blumer shelf = advanced/metastatic disease

Board Question Stem Patterns

— Older patient, painless jaundice, weight loss, palpable non-tender gallbladder, dark urine, light stools

— Answer cascade: Pancreas-protocol CT → mass identified → EUS-FNB for tissue if neoadjuvant/non-resectable → resectability staging → treatment

— Lean older adult, new diabetes, unintentional weight loss, vague abdominal symptoms

— Trap: managing diabetes as primary

— Answer: abdominal imaging to evaluate for pancreatic malignancy

— Recurrent unprovoked migratory thrombophlebitis or DVT in older patient with weight loss

— Answer: CT abdomen/pelvis for occult malignancy + LMWH or apixaban

— Fever, RUQ pain, jaundice (± shock/AMS)

— Answer: IV antibiotics + urgent ERCP with biliary decompression, then full workup

— CT findings with vascular involvement (e.g., SMA contact >180°)

— Answer: borderline resectable/locally advanced → neoadjuvant chemo, not upfront Whipple

— ECOG 0–1, fit → FOLFIRINOX

— ECOG 2 or marginal → gem + nab-paclitaxel or gemcitabine alone

— Germline BRCA2 + platinum response → olaparib maintenance

— Newly diagnosed PDAC, no family history mentioned

— Answer: Germline testing for ALL PDAC patients (universal)

— Diffusely enlarged "sausage" pancreas, elevated IgG4, mild jaundice

— Answer: Trial corticosteroids, not Whipple

— POD 3 fever + drain amylase >3x serum → pancreatic fistula management

— Delayed gastric emptying → supportive, NG decompression, prokinetics

— Metastatic PDAC, severe back pain refractory to opioids

— Answer: Celiac plexus neurolysis + early palliative care

— Whipple at low-volume hospital

— Answer: Refer to high-volume center for improved outcomes

— Strong clinical suspicion but normal CA 19-9

— Answer: Pursue imaging anyway; CA 19-9 has limited sensitivity

Board pearl: Step 3 PDAC stems emphasize the next best step in workup or management, not the diagnosis itself — practice the order of CT → EUS → staging → multidisciplinary decision.

Pattern 1 — Classic head-of-pancreas PDAC:

Pattern 2 — New-onset diabetes paraneoplastic:

Pattern 3 — Trousseau syndrome:

Pattern 4 — Cholangitis on top of PDAC:

Pattern 5 — Resectability decision:

Pattern 6 — Choosing chemo regimen:

Pattern 7 — Genetic testing:

Pattern 8 — Autoimmune pancreatitis mimic:

Pattern 9 — Post-Whipple complication:

Pattern 10 — Palliative:

Pattern 11 — Quality/systems:

Pattern 12 — Lewis-negative CA 19-9:

One-Line Recap

Pancreatic adenocarcinoma is a highly lethal malignancy that should be suspected in any older patient with painless jaundice, weight loss, or unexplained new-onset diabetes — diagnosed with multiphase pancreas-protocol CT plus EUS-FNB and managed by a multidisciplinary team using staging-based decisions (resectable/borderline/locally advanced/metastatic), neoadjuvant or adjuvant FOLFIRINOX in fit patients, biliary decompression for jaundice, universal germline testing, and early palliative care integration.

Board pearl: Three sentences capture the whole topic — suspect early in painless jaundice and new diabetes, stage with CT before treating, and integrate palliative care from day one alongside aggressive oncologic therapy in fit patients.

Diagnosis: painless jaundice + Courvoisier + weight loss → pancreas-protocol CT first; EUS-FNB for tissue when neoadjuvant or non-operative path planned; CA 19-9 for monitoring (Lewis-negative 5–10% caveat); universal germline testing in every PDAC patient.

Staging-driven treatment: only 15–20% resectable at diagnosis; resectable → consider neoadjuvant or upfront Whipple at high-volume center + adjuvant mFOLFIRINOX; borderline/locally advanced → neoadjuvant chemo ± radiation; metastatic → FOLFIRINOX vs gem/nab-paclitaxel by ECOG; olaparib maintenance for BRCA-mutated platinum-responders.

Supportive care is core curriculum: biliary stenting (SEMS), PERT for exocrine insufficiency, glycemic control (type 3c diabetes), VTE prophylaxis (high Khorana score), nutritional support, celiac plexus neurolysis for refractory pain, and early concurrent palliative care.

Step 3 systems and safety: high-volume center referral for Whipple, structured post-discharge follow-up within 1–2 weeks, transitions-of-care medication reconciliation (PERT, PPI, insulin, anticoagulant), genetic counseling for relatives of mutation carriers, advance care planning at diagnosis, and honest prognostic communication using shared decision-making.